Accès ouvert
2025
article
OpenAlex
Sofie Mesens, Andrew D. Krystal, Rama Melkote, Haiyan Xu et autres
Importance: Existing pharmacological treatments for insomnia have significant limitations. Objective: To assess the effective dose range, safety, and tolerability of the novel selective orexin-2 receptor antagonist seltorexant in insomnia disorder. Design, Setting, and Participants: This randomized, double-blind, active- and placebo-controlled, dose-finding, polysomnography …
us
(code pays fourni par la source)
2024
article
OpenAlex
Sydney H James, Anthony O. Ahmed, Philip D. Harvey, Jay Saoud et autres
us, cy
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Philip D. Harvey, Michael Davidson, Jay Saoud, Ramana Kuchibhatla et autres
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Michael Davidson, R. Luthringer, Jay Saoud, Alex Richter
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Laurie Thiesse, Luc Staner, Patrice Bourgin, Henri Comtet et autres
Polysomnographic sleep architecture parameters are commonly used to diagnose or evaluate treatment of sleep disorders. Polysomnography (PSG) having practical constraints, the development of wearable devices and algorithms to monitor and stage sleep is rising. Beside pure validation studies, it is necessary for …
fr, us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Antoine Viola, Laurie Thiesse, Luc Staner, Gil Fuchs et autres
Abstract Introduction A number of studies have evaluated epoch-by-epoch agreement between 2 technologists in scoring individual sleep stage. Scoring for the specific sleep stages average agreement ranged from 20% to 90% in different studies. The goal of this study is to evaluate …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jonathan Rabinowitz, Corinne Staner, Jay Saoud, Mark Weiser et autres
-adrenergic receptors, but no dopaminergic binding affinities. In 2 randomized controlled trials (RCT), treatment improved negative symptoms of schizophrenia and social functioning among patients with moderate to severe negative symptoms. We report results of the protocol specified analysis of 2 open-label extension …
il, us, cy
(code pays fourni par la source)
2023
article
OpenAlex
Antoine Viola, Laurie Thiesse, Luc Staner, Gil Fuchs et autres
fr, us
(code pays fourni par la source)
2023
article
OpenAlex
Antoine Viola, Laurie Thiesse, Luc Staner, Gil Fuchs et autres
fr, us
(code pays fourni par la source)
2023
article
OpenAlex
Antoine Viola, Laurie Thiesse, Georg Dorffner, Gil Fuchs et autres
fr, at
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Laurie Thiesse, Luc Staner, Gil Fuchs, Débora Kirscher et autres
The visual scoring of gold standard polysomnography (PSG) is known to present inter- and intra-scorer variability. Previously, Somno-Art Software, a cardiac based sleep scoring algorithm, has been validated in comparison to 2 expert visual PSG scorers. The goal of this research is …
fr, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noël et autres
BACKGROUND: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar …
cy, us, il
(code pays fourni par la source)